Catalyst Pharmaceuticals Inc.
CPRX | NASDAQ
$31.49
$0 (0.00%)
Jul 15, 2026, 9:30 AM ET · Market open
Market Data
Market Cap $3.85B
Enterprise Value $3.1B
Beta 0.74
Average Volume 2.35M
Shares Outstanding (Diluted) 126.9M
Shares Change YoY -0.04%
Institutional Ownership 85.52%
Exchange NASDAQ
ISIN US14888U1016
Price Performance
Price Change 1M 0.4%
Price Change 3M 19.9%
Price Change 6M 34.7%
Price Change YTD 36.0%
Price Change 1Y 48.7%
Price Change 3Y 130.5%
Price Change 5Y 467.4%
1M CAGR (ann.) 0.7%
1Y CAGR (ann.) 49.7%
5Y CAGR (ann.) 41.8%
All-Time CAGR 8.7%
Valuation
PE Ratio 18.20
Forward PE 12.84
PEG Ratio 2.07
Forward PEG 0.75
PS Ratio 6.46
Forward PS 5.40
PB Ratio 3.81
P/FCF Ratio 18.52
P/Adj. FCF Ratio 20.37
P/OCF Ratio 18.52
EV/Sales 5.20
EV/EBIT 11.26
EV/EBITDA 9.89
EV/FCF 14.90
Earnings Yield 5.5%
FCF Yield 5.4%
Adj. FCF Yield 4.9%
Financial Health
Net Cash $753.62M
Total Debt $2.24M
Cash & Short-Term Investments $755.86M
Total Assets $1.15B
Current Ratio 7.10
Quick Ratio 6.84
Debt / Equity Ratio 0.00
Debt / EBITDA 0.01
Debt / FCF 0.01
OCF / Debt 93.16
Interest Coverage 0.00
Altman Z-Score 19.94
Piotroski F-Score 3
Margins & Profitability
Gross Profit Margin 82.3%
Operating Profit Margin 44.8%
EBITDA Margin 56.1%
Net Profit Margin 37.1%
FCF Margin 34.9%
Adj. FCF Margin 31.7%
SBC / Revenue 4.2%
SBC Impact (per share) -9.1%
Returns
Return on Assets 19.3%
Return on Equity 23.6%
Return on Invested Capital 19.7%
Return on Capital Employed 26.4%
Return on Tangible Assets 21.6%
Historical Growth (CAGR)
Revenue CAGR 3Y 32.5%
Revenue CAGR 5Y 37.8%
Revenue CAGR 10Y 31.8%
EPS CAGR 3Y 25.3%
EPS CAGR 5Y 20.5%
EPS CAGR 10Y 38.6%
FCF CAGR 3Y 11.1%
FCF CAGR 5Y 38.6%
FCF CAGR 10Y 41.2%
Analyst Forecasts
Analyst Rating Buy
Analyst Count 16
EPS Growth Next 3Y 14.9%
Revenue Growth Next 3Y 13.7%
Earnings Date Aug 4, 2026
EPS Estimate (next Q) $0.48
EPS Growth Est (next Q) 11.6%
Revenue Est (next Q) $155.79M
Revenue Growth Est (next Q) 6.3%
Fair Value Estimates
Graham Number $17.95
Graham Upside -43.0%
Lynch Fair Value $35.52
Lynch Upside 12.8%
Price Target $31.75
Price Target Upside 0.8%
Cash Flow
Operating Cash Flow $208.21M
Free Cash Flow $208.13M
Adj. Free Cash Flow $189.2M
FCF Per Share $1.70
OCF Per Share $1.70
OCF/S Ratio 34.9%
Income Statement
Revenue $596.96M
Gross Profit $491.44M
Operating Income $267.64M
EBITDA $313.67M
Net Income $221.32M
EPS (Diluted) $1.73
Revenue / Employee $3.3M
Profit / Employee $1.22M
Employees 181
Add to Watchlist
Select watchlists to add or remove CPRX